A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03598790
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
1353
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque Psoriasis
Interventions
DRUG:
Bimekizumab
Sponsor
UCB Biopharma SRL